PMID- 24578833
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140228
LR  - 20211021
IS  - 2074-1804 (Print)
IS  - 2074-1812 (Electronic)
IS  - 2074-1804 (Linking)
VI  - 15
IP  - 8
DP  - 2013 Aug
TI  - Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with 
      Moderate to Severe Crohn's Disease? A Meta-analysis of Controlled Clinical 
      Trials.
PG  - 668-75
LID - 10.5812/ircmj.11258 [doi]
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) antibodies are currently used in 
      patients with moderate to severe Crohn's disease (CD) who are unresponsive to 
      conventional therapies. Certolizumab pegol (Cp) is one of the anti-TNF-alpha agents 
      introduced for the management of CD and rheumatoid arthritis. OBJECTIVES: The aim 
      of this meta-analysis is to assess the efficacy of Cp in inducing clinical 
      response and remission in CD and the associated adverse events. The effect of Cp 
      in terms of CD patients' C-reactive protein (CRP) level was also studied. 
      PATIENTS AND METHODS: Literature was searched for studies investigated the 
      efficacy of Cp on inducing clinical response and maintaining remission in the 
      patients with CD between 1966 and July 2012. RESULTS: Among 165 potentially 
      relevant studies, six with a total of 1695 patients met the inclusion criteria 
      and were meta-analyzed. In comparison to control groups, patients who received Cp 
      had a relative risk (RR) of 1.38 with absolute risk reduction (ARR) = 0.12; 95% 
      CI = 0.03 to 0.21), number needed for treatment (NNT) = 9; P < 0.0001 ) for 
      clinical response and RR of 1.54 (ARR = 0.09; 95% CI = -0.0198 to 0.2), (NNT = 
      12; P < 0.0001) for maintenance of clinical remission and non-significant RR of 
      1.24 (P = 0.052) for induction of clinical remission. Baseline CRP did not 
      significantly alter the magnitude or response. Adverse events were not 
      significantly different among patients receiving Cp comparing to placebo. 
      CONCLUSIONS: Cp is effective for inducing clinical response and maintenance of 
      clinical remission in patients with moderate to severe CD with similar 
      side-effect profile as the control arms.
FAU - Nikfar, Shekoufeh
AU  - Nikfar S
AD  - Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of 
      Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran ; Food and Drug 
      Organization, Ministry of Health and Medical Education, Tehran, IR Iran.
FAU - Ehteshami-Afshar, Solmaz
AU  - Ehteshami-Afshar S
AD  - Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR 
      Iran ; Faculty of Pharmacy, and Pharmaceutical Sciences Research Center, Tehran 
      University of Medical Sciences, Tehran, IR Iran.
FAU - Abdollahi, Mohammad
AU  - Abdollahi M
AD  - Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of 
      Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran ; Faculty of 
      Pharmacy, and Pharmaceutical Sciences Research Center, Tehran University of 
      Medical Sciences, Tehran, IR Iran.
LA  - eng
PT  - Journal Article
DEP - 20130805
PL  - Estonia
TA  - Iran Red Crescent Med J
JT  - Iranian Red Crescent medical journal
JID - 101319850
PMC - PMC3918190
OTO - NOTNLM
OT  - Certolizumab Pegol
OT  - Crohn's Disease
OT  - Meta-analysis
EDAT- 2014/03/01 06:00
MHDA- 2014/03/01 06:01
PMCR- 2013/08/01
CRDT- 2014/03/01 06:00
PHST- 2013/03/18 00:00 [received]
PHST- 2013/05/30 00:00 [accepted]
PHST- 2014/03/01 06:00 [entrez]
PHST- 2014/03/01 06:00 [pubmed]
PHST- 2014/03/01 06:01 [medline]
PHST- 2013/08/01 00:00 [pmc-release]
AID - 10.5812/ircmj.11258 [doi]
PST - ppublish
SO  - Iran Red Crescent Med J. 2013 Aug;15(8):668-75. doi: 10.5812/ircmj.11258. Epub 
      2013 Aug 5.